Growth Metrics

Supernus Pharmaceuticals (SUPN) Cash from Operations (2016 - 2026)

Supernus Pharmaceuticals has reported Cash from Operations over the past 15 years, most recently at 19861000.0 for Q4 2025.

  • Quarterly Cash from Operations fell 55.27% to 19861000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 47331000.0 through Dec 2025, down 72.47% year-over-year, with the annual reading at 47331000.0 for FY2025, 72.47% down from the prior year.
  • Cash from Operations was 19861000.0 for Q4 2025 at Supernus Pharmaceuticals, up from 61664000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 71119000.0 in Q2 2022 and troughed at 61664000.0 in Q3 2025.
  • The 5-year median for Cash from Operations is 36037500.0 (2021), against an average of 28716000.0.
  • Year-over-year, Cash from Operations surged 1041.93% in 2023 and then crashed 215.22% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 48763000.0 in 2021, then plummeted by 43.47% to 27564000.0 in 2022, then skyrocketed by 63.1% to 44958000.0 in 2023, then fell by 1.23% to 44406000.0 in 2024, then plummeted by 55.27% to 19861000.0 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Cash from Operations are 19861000.0 (Q4 2025), 61664000.0 (Q3 2025), and 58535000.0 (Q2 2025).